Core Insights - Viking Therapeutics, Inc. (NASDAQ: VKTX) has remained resilient despite negative market reactions following the results from its VENTURE-Oral study of VK2735, indicating potential future catalysts that could influence market sentiment positively or negatively [1] Company Summary - The company is focused on trading around significant events such as trial results and NDA/BLA approvals, which are critical for biotech stocks [1]